# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN-TD
- Date: 1996-01-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Hepatitis C results and hepatology consultation. **S**

## History of present illness

Mr. Knievel returns two weeks after his first visit. The hepatitis C antibody was positive and the reflex test found HCV RNA, 2.35 million IU/mL, genotype 1a. Hepatitis B surface antigen, core antibody and surface antibody were all negative, so he has never had hepatitis B and is not immune; hepatitis A IgG was negative; HIV was negative. The ultrasound a week ago showed a nodular liver, a 14.2 cm spleen, no liver mass and no ascites. Dr. Okonkwo of hepatology saw him this morning, and transient elastography in her clinic measured liver stiffness at 26.8 kPa. He stopped ibuprofen and omeprazole after the first visit and uses acetaminophen twice a day and diclofenac gel on his knees; pain is a little worse in the mornings. He has cut down to about two drinks most evenings. He has had no abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Hepatitis C | Antibody positive; HCV RNA 2.35 million IU/mL; genotype 1a; never treated |
| Other serology | Hepatitis B: not infected, not immune. Hepatitis A: not immune. HIV negative |
| Staging | FIB-4 4.94; liver stiffness 26.8 kPa; nodular liver and 14.2 cm spleen on ultrasound; platelets 118 |
| Liver function | Bilirubin 1.1 mg/dL, albumin 3.6 g/dL, INR 1.1, no ascites or encephalopathy: Child-Pugh A5; MELD-Na 8 |
| Alcohol | Cut down to about two drinks most evenings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for months; no fever or weight loss |
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting of blood |
| Integumentary | Positive | Small red spots on the chest; no yellowing or itching |
| Neurological | Negative | No confusion, sleep reversal or tremor |
| Musculoskeletal | Positive | Hip, knee and back pain, 6 of 10, worse in the mornings since stopping ibuprofen |
| Psychiatric | Positive | Worried about the diagnosis; PHQ-9 6; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day **S**
- Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day **S**
- Carvedilol 6.25 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/82 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 85.6 kg; BMI 27 kg/m². All vital signs are synthetic.

Liver stiffness (transient elastography): 26.8 kPa (high); PHQ-9: 6; AUDIT-C: 4; Pain (0 to 10): 6. All results are synthetic.

## Change since baseline

- AUDIT-C: 7 at baseline, 4 at this visit **S**
- Pain (0 to 10): 7 at baseline, 6 at this visit **S**

## Immunizations given today

- Hepatitis A vaccine, adult, dose 1 of 2 **S**
- Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 85.6 kg; blood pressure 136/82, pulse 78 |
| Eyes | No scleral icterus |
| Skin | Six spider angiomas on the chest and shoulders; palmar erythema; no jaundice or bruising |
| Abdomen | Liver edge firm, 2 cm below the costal margin; spleen tip palpable; no shifting dullness |
| Extremities | No leg swelling |
| Feet | Monofilament sensation intact; pulses present; no ulcers |
| Neurological | No asterixis; oriented |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic hepatitis C, genotype 1a, treatment-naive** (B18.2). Chronic hepatitis C, most likely from transfusions after his crashes before blood was screened for it. He is eligible for the AASLD-IDSA simplified pathway for compensated cirrhosis: no prior treatment, Child-Pugh A, eGFR above 30, hepatitis B surface antigen negative, no known liver cancer and no transplant. Dr. Okonkwo recommends sofosbuvir-velpatasvir, one tablet daily for 12 weeks, to start once it is approved. The interaction check is clean now that omeprazole has stopped; atorvastatin can be used with muscle-pain monitoring. **S**
   - Sofosbuvir-velpatasvir for 12 weeks when approved.
   - Avoid proton pump inhibitors during treatment; if acid treatment is needed, famotidine up to 40 mg twice a day taken with the tablet or 12 hours apart.
   - HCV RNA 12 or more weeks after the last dose.
2. **Compensated cirrhosis, Child-Pugh A5, MELD-Na 8** (K74.69). FIB-4 above 3.25, liver stiffness above 12.5 kPa, a nodular liver, splenomegaly and platelets below 150 all point to cirrhosis, with alcohol as a cofactor. It is compensated. Cirrhosis carries a lifelong risk of liver cancer, so surveillance continues after cure. No transplant evaluation is needed now; referral would follow any decompensation or a MELD-Na of 15. **S**
   - Ultrasound with alpha-fetoprotein every six months, next in July.
   - Hepatitis A and B vaccines today.
   - Report abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes the same day.
3. **Clinically significant portal hypertension** (K76.6). A liver stiffness of 25 kPa or more establishes clinically significant portal hypertension under Baveno VII. A non-selective beta-blocker lowers the risk of decompensation, and carvedilol is preferred; a patient who takes one does not need screening endoscopy for varices. **S**
   - Carvedilol 6.25 mg daily, raised to 12.5 mg at the next visit if systolic pressure stays above 100.
   - No screening endoscopy while he takes carvedilol.
4. **Type 2 diabetes in cirrhosis** (E11.65). A1c 7.4% in January; in cirrhosis the A1c can read falsely low, so a continuous glucose monitor will guide treatment. Metformin is safe in compensated cirrhosis with normal kidney function if he stops drinking. LDL 112 mg/dL: a statin is indicated for diabetes at his age and is safe in compensated cirrhosis. **S**
   - Atorvastatin 20 mg daily from today.
   - Continuous glucose monitor ordered.
   - Eye examination referral.
5. **Raised transaminases and low platelets** (R74.01). Explained by chronic hepatitis C with cirrhosis; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hepatitis C antibody with reflex HCV RNA and genotype | At diagnosis | Up to date | Antibody positive; HCV RNA 2.35 million IU/mL; genotype 1a (first-visit sample) |
| Laboratory | Hepatitis B surface antigen, core antibody and surface antibody | Before any HCV treatment | Up to date | All negative: no reactivation risk; vaccinate |
| Laboratory | HIV and hepatitis A IgG | Before HCV treatment | Up to date | HIV negative; hepatitis A not immune |
| Laboratory | FIB-4 | At diagnosis | Up to date | 4.94 from the first-visit results (age 57, AST 96, ALT 88, platelets 118): cirrhosis likely |
| Imaging | Transient elastography | At diagnosis | Completed today | 26.8 kPa: cirrhosis with clinically significant portal hypertension |
| Imaging | Liver ultrasound | Within six months before treatment; every six months in cirrhosis | Up to date | A week ago: nodular liver, splenomegaly, no mass, no ascites |
| Examination | Child-Pugh class and MELD-Na | At diagnosis and every six months in cirrhosis | Completed today | Child-Pugh A5; MELD-Na 8 |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Medication safety | Drug interaction review before HCV treatment | Before treatment | Completed today | Omeprazole and ibuprofen stopped; atorvastatin allowed with monitoring; no amiodarone; no herbal supplements |
| Medication safety | Non-selective beta-blocker for clinically significant portal hypertension | Start, then titrate to blood pressure and heart rate | Completed today | Carvedilol 6.25 mg daily started |
| Examination | Screening endoscopy for varices | Only if a beta-blocker cannot be taken | Not indicated | He takes carvedilol, so Baveno VII does not call for screening endoscopy |
| Medication safety | Hepatitis A and B vaccination | At diagnosis of chronic liver disease if not immune | Completed today | Hepatitis A dose 1 and hepatitis B (CpG-adjuvanted) dose 1 today |
| Laboratory | A1c and glucose monitoring in cirrhosis | Every three months when not at goal | Up to date | A1c 7.4% in January; continuous glucose monitor ordered because the A1c can read falsely low |
| Examination | Diabetic foot examination | Yearly | Completed today | Monofilament sensation and pulses normal |
| Referral | Diabetic eye examination | Yearly | Referred | Referred; last examination over three years ago |
| Medication safety | Statin for diabetes | Age 40 to 75 with diabetes | Completed today | Atorvastatin 20 mg started; safe in compensated cirrhosis |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 4: cutting down; goal is no alcohol |
| Survey | Pain score and function | Each visit | Completed today | 6 of 10 after stopping ibuprofen; acetaminophen up to 2 g a day and topical diclofenac |
| Referral | Hepatology | At diagnosis of hepatitis C with cirrhosis | Completed today | Seen this morning; recommendations in the consultation note |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 6; no thoughts of self-harm |

## Goal progress

- Hepatitis C confirmed or excluded and liver disease staged within three weeks. Outcome by 1996-01-26: Chronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks. **S**
- Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment. In progress; target 1996-08-17. **S**
- No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 15. In progress; target 1996-08-17. **S**
- No alcohol. In progress; target 1996-08-17. **S**
- Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids. In progress; target 1996-08-17. **S**
- Glucose management indicator below 7% without hypoglycemia. In progress; target 1996-08-17. **S**
- Vitamin D replete and osteoporosis treatment started; no falls with injury. In progress; target 1996-08-17. **S**

## Medication changes

- Started: Carvedilol 6.25 mg oral tablet, one tablet daily **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Guideline basis

- AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025), U.S. National Library of Medicine, DailyMed (Gilead Sciences label)
- Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023), American Association for the Study of Liver Diseases
- de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022), Baveno VII Faculty (Journal of Hepatology)
- Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024), American Association for the Study of Liver Diseases
- Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021), American Association for the Study of Liver Diseases
- Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019), American Association for the Study of Liver Diseases
- Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018), American Association for the Study of Liver Diseases (Clinical Liver Disease)
- Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022), Centers for Disease Control and Prevention
- American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026), American Diabetes Association
- American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026), American Diabetes Association
- Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020), U.S. Preventive Services Task Force
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Physical therapy assessment next week. Antiviral treatment to start at the next visit in four weeks, with the second hepatitis B dose and carvedilol titration. Call for abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. **S**
- Next scheduled visit 1996-02-23: day 1 of sofosbuvir-velpatasvir: drug interaction check, carvedilol titration, glucose monitoring, vitamin D, and the bone density plan. **S**
